Tumor Biology

, Volume 36, Issue 12, pp 9857–9864 | Cite as

Nonsecreted cytoplasmic alpha-fetoprotein: a newly discovered role in intracellular signaling and regulation. An update and commentary

Research Article

Abstract

The concept of a non-secreted cytoplasmic-bound form of alpha-fetoprotein is not a new notion in AFP biological activities. Cytoplasmic AFP (CyAFP) is a long known but forgotten protein in search of a function other than a histochemical biomarker. In this report, CyAFP is presented as an “old” protein with a newly described intracellular function. In 1976, CyAFP was shown to be a product of hepatoma cells utilizing 14Cleucine incorporation and demonstrated by autoradiographic procedures. The synthesis of CyAFP without secretion was demonstrated to occur in both malignant and non-malignant cells encompassing hepatomas, ascite fluid cells, immature rodent uterus, MCF-7 breast cancers, and cytosols from human breast cancer patients. Using computer protein matching and alignments in AFP versus members of the nuclear receptor superfamily, a consecutive series of leucine zipper (heptad) repeats in AFP was previously reported, suggesting the possibility for protein-to-protein interactions. The potential for heptad heterodimerization between protein-binding partners provided the rationale for proposing that CyAFP might have the capability to form molecular hetero-complexes with cytoplasmic based transcription factors. More recent investigations have now provided experimental evidence that CyAFP is capable of colocalizing and interacting with transcription-associated factors. Such proteins can modulate intracellular signaling leading to regulation of transcription factors and initiation of growth in human cancer cells. Although circulating serum AFP is known as a growth-enhancing factor during development, cytoplasmic AFP has a lethal role in the oncogenesis, growth, and metastasis of adult liver cancer.

Keywords

Alpha-fetoprotein Caspase-3 PI3K/AKT Retinoic acid receptor PTEN GADD153 Dimerization Heptad repeats 

Notes

Acknowledgments

The author wishes to extend his thanks and gratitude to Ms. Tracy Godfrey for the typing and processing of this manuscript. The author also wishes to dedicate this paper to the memory of Dr. Edward J. Sarcione for his 1976 discovery of cytoplasmic alpha-fetoprotein.

Conflicts of interest

None

References

  1. 1.
    Mizejewski GJ. Alpha-fetoprotein structure and function: Relevance to isoforms, epitopes, and conformational variants. Exp Biol Med. 2001;226:377–408.Google Scholar
  2. 2.
    Mizejewski GJ. Biological roles of alpha-fetoprotein during pregnancy and perinatal development. Exp Biol Med. 2004;229:439–63.Google Scholar
  3. 3.
    Kuo MT, Iyer B, Wu JR, Lapeyre JN, Becker FF. Methylation of the alpha-fetoprotein gene in productive and nonproductive rat hepatocellular carcinomas. Cancer Res. 1984;44:1642–7.PubMedGoogle Scholar
  4. 4.
    Sell S, Skelly H. Tissue sites of alpha fetoprotein synthesis by the rat during pregnancy and hepatoma growth. J Natl Cancer Inst. 1976;56:645–8.CrossRefPubMedGoogle Scholar
  5. 5.
    Sell S. Heterogeneity of alpha-fetoprotein (afp) and albumin containing cells in normal and pathological permissive states for afp production: Afp containing cells induced in adult rats recapitulate the appearance of afp containing hepatocytes in fetal rats. Onco Dev Biol Med. 1980;1:93–105.Google Scholar
  6. 6.
    Mizejewski GJ. Biological role of alpha-fetoprotein in cancer: prospects for anticancer therapy. Expert Rev Anticancer Ther. 2002;2:709–35.CrossRefPubMedGoogle Scholar
  7. 7.
    Mizejewski GJ. Alpha-fetoprotein as a biologic response modifier: relevance to domain and subdomain structure. Proceedings Soc Exp Biol Med Soc Exp Biol Med. 1997;215:333–62.CrossRefGoogle Scholar
  8. 8.
    Walhof CM, Van Sonderen L, Voute PA, Delemarre JF. Half-life of alpha-fetoprotein in patients with a teratoma, endodermal sinus tumor, or hepatoblastoma. Pediatr Hematol Oncol. 1988;5:217–27.CrossRefPubMedGoogle Scholar
  9. 9.
    Sarcione EJ, Smalley JR. Intracellular synthesis of alpha-fetoprotein and fibrinogen without secretion by zajdela rat ascites hepatoma cells. Cancer Res. 1976;36:3203–6.PubMedGoogle Scholar
  10. 10.
    Sarcione EJ, Biddle W. Elevated serum alpha fetoprotein levels in postmenopausal women with primary breast carcinoma. Dis Markers. 1987;5:75–9.PubMedGoogle Scholar
  11. 11.
    Sarcione EJ, Hart D. Biosynthesis of alpha fetoprotein by mcf-7 human breast cancer cells. Int J Cancer. 1985;35:315–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Sarcione EJ, Zloty M, Delluomo DS, Mizejewski G, Jacobson H. Detection and measurement of alpha-fetoprotein in human breast cancer cytosol after treatment with 0.4 m potassium chloride. Cancer Res. 1983;43:3739–41.PubMedGoogle Scholar
  13. 13.
    Smalley JR, Sarcione EF. Synthesis of alpha fetoprotein by immature rat uterus. Biochem Biophys Res Commun. 1980;92:1429–34.CrossRefPubMedGoogle Scholar
  14. 14.
    Biddle W, Sarcione EJ. Specific cytoplasmic alpha-fetoprotein binding protein in mcf-7 human breast cancer cells and primary breast cancer tissue. Breast Cancer Res Treat. 1987;10:279–86.CrossRefPubMedGoogle Scholar
  15. 15.
    Mizejewski GJ. Alpha-fetoprotein binding proteins: Implications for transmembrane passage and subcellular localization. Life Sci. 1995;56:1–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Peters EH, Nishi S, Miura K, Lorscheider FL, Dixon GH, Tamaoki T. In vitro synthesis of murine pre-alpha-fetoprotein. Cancer Res. 1979;39:3702–6.PubMedGoogle Scholar
  17. 17.
    Morinaga T, Sakai M, Wegmann TG, Tamaoki T. Primary structures of human alpha-fetoprotein and its mrna. Proc Natl Acad Sci U S A. 1983;80:4604–8.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Butterfield LH, Economou JS, Gamblin TC, Geller DA. Alpha fetoprotein DNA prime and adenovirus boost immunization of two hepatocellular cancer patients. J Transl Med. 2014;12:86.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Butterfield LH, Meng WS, Koh A, Vollmer CM, Ribas A, Dissette VB, et al. T cell responses to hla-a*0201-restricted peptides derived from human alpha fetoprotein. J Immunol. 2001;166:5300–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Mizejewski GJ. Review of the putative cell-surface receptors for alpha-fetoprotein: Identification of a candidate receptor protein family. Tumour Biol. 2011;32:241–58.CrossRefPubMedGoogle Scholar
  21. 21.
    Mizejewski GJ. Review of the adenocarcinoma cell surface receptor for human alpha-fetoprotein; proposed identification of a widespread mucin as the tumor cell receptor. Tumour Biol. 2013;34:1317–36.CrossRefPubMedGoogle Scholar
  22. 22.
    Mizejewski GJ. The adenocarcinoma cell surface mucin receptor for alpha-fetoprotein: is the same receptor present on circulating monocytes and macrophages? A commentary. Tumour Biol. 2014;35:7397–402.CrossRefPubMedGoogle Scholar
  23. 23.
    Laborda J, Naval J, Allouche M, Calvo M, Georgoulias V, Mishal Z, et al. Specific uptake of alpha-fetoprotein by malignant human lymphoid cells. Int J Cancer. 1987;40:314–8.CrossRefPubMedGoogle Scholar
  24. 24.
    Kornilova ES. Receptor-mediated endocytosis and cytoskeleton. Biochem Biokhimiia. 2014;79:865–78.CrossRefGoogle Scholar
  25. 25.
    Hajeri-Germond M, Trojan J, Uriel J. Alpha-fetoprotein uptake by differentiating neuroretinal structures of the chick embryo. Dev Neurosci. 1991;13:164–70.CrossRefPubMedGoogle Scholar
  26. 26.
    Torres JM, Geuskens M, Uriel J. Receptor-mediated endocytosis and recycling of alpha-fetoprotein in human b-lymphoma and t-leukemia cells. Int J Cancer. 1991;47:110–7.CrossRefPubMedGoogle Scholar
  27. 27.
    Mizejewski G. Review of peptides as receptor ligand drugs and their relationship to g-coupled signal transduction. Exp Opin Investig Drugs. 2001;10:1063–73.CrossRefGoogle Scholar
  28. 28.
    Meng WS, Butterfield LH, Ribas A, Heller JB, Dissette VB, Glaspy JA, et al. Fine specificity analysis of an hla-a2.1-restricted immunodominant t cell epitope derived from human alpha-fetoprotein. Mol Immunol. 2000;37:943–50.CrossRefPubMedGoogle Scholar
  29. 29.
    Petropoulos C, Andrews G, Tamaoki T, Fausto N. Alpha-fetoprotein and albumin mrna levels in liver regeneration and carcinogenesis. J Biol Chem. 1983;258:4901–6.PubMedGoogle Scholar
  30. 30.
    Petropoulos CJ, Yaswen P, Panzica M, Fausto N. Cell lineages in liver carcinogenesis: possible clues from studies of the distribution of alpha-fetoprotein rna sequences in cell populations isolated from normal, regenerating, and preneoplastic rat livers. Cancer Res. 1985;45:5762–8.PubMedGoogle Scholar
  31. 31.
    Chou JY, Savitz AJ. Alpha-fetoprotein synthesis in transformed fetal rat liver cells. Biochem Biophys Res Commun. 1986;135:844–51.CrossRefPubMedGoogle Scholar
  32. 32.
    Lemire JM, Fausto N. Multiple alpha-fetoprotein rnas in adult rat liver: cell type-specific expression and differential regulation. Cancer Res. 1991;51:4656–64.PubMedGoogle Scholar
  33. 33.
    Morinaga T, Sakai M, Wegmann TG, Tamaoki T. Alphafetoprotein messenger rna in human embryonal carcinoma grown in nude mice, and cloning of its complementary DNA. Onco Dev Biol Med. 1982;3:301–13.Google Scholar
  34. 34.
    Mizejewski GJ. An apparent dimerization motif in the third domain of alpha-fetoprotein: molecular mimicry of the steroid/thyroid nuclear receptor superfamily. Bioessays. 1993;15:427–32.CrossRefPubMedGoogle Scholar
  35. 35.
    Mizejewski GJ. Alpha-fetoprotein signal sequences: a proposed mechanism for subcellular localization and organelle targeting. J Theor Biol. 1995;176:103–13.CrossRefPubMedGoogle Scholar
  36. 36.
    Forman BM, Samuels HH. Interactions among a subfamily of nuclear hormone receptors: the regulatory zipper model. Mol Endocrinol. 1990;4:1293–301.CrossRefPubMedGoogle Scholar
  37. 37.
    Rosen ED, O'Donnell AL, Koenig RJ. Protein-protein interactions involving erba superfamily receptors: through the trapdoor. Mol Cell Endocrinol. 1991;78:C83–8.CrossRefPubMedGoogle Scholar
  38. 38.
    Dauphinee MJ, Mizejewski GJ. Human alpha-fetoprotein contains potential heterodimerization motifs capable of interaction with nuclear receptors and transcription/growth factors. Med Hypotheses. 2002;58:453–61.CrossRefPubMedGoogle Scholar
  39. 39.
    Adam SA, Gerace L. Cytosolic proteins that specifically bind nuclear location signals are receptors for nuclear import. Cell. 1991;66:837–47.CrossRefPubMedGoogle Scholar
  40. 40.
    Li M, Liu X, Zhou S, Li P, Li G. Effects of alpha fetoprotein on escape of bel 7402 cells from attack of lymphocytes. BMC Cancer. 2005;5:96.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Li MS, Ma QL, Chen Q, Liu XH, Li PF, Du GG, et al. Alpha-fetoprotein triggers hepatoma cells escaping from immune surveillance through altering the expression of fas/fasl and tumor necrosis factor related apoptosis-inducing ligand and its receptor of lymphocytes and liver cancer cells. World J Gastroenterol. 2005;11:2564–9.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Li M, Zhou S, Liu X, Li P, McNutt MA, Li G. Alpha-fetoprotein shields hepatocellular carcinoma cells from apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand. Cancer Lett. 2007;249:227–34.CrossRefPubMedGoogle Scholar
  43. 43.
    Mizejewski GJ. Therapeutic use of human alpha-fetoprotein in clinical patients: is a cancer risk involved? Int J Cancer. 2011;128:239–42.CrossRefPubMedGoogle Scholar
  44. 44.
    Li M, Li H, Li C, Zhou S, Guo L, Liu H, et al. Alpha fetoprotein is a novel protein-binding partner for caspase-3 and blocks the apoptotic signaling pathway in human hepatoma cells. Int J Cancer. 2009;124:2845–54.CrossRefPubMedGoogle Scholar
  45. 45.
    Dudich E, Semenkova L, Dudich I, Denesyuk A, Tatulov E, Korpela T. Alpha-fetoprotein antagonizes x-linked inhibitor of apoptosis protein anticaspase activity and disrupts xiap-caspase interaction. FEBS J. 2006;273:3837–49.CrossRefPubMedGoogle Scholar
  46. 46.
    Semenkova L, Dudich E, Dudich I, Tokhtamisheva N, Tatulov E, Okruzhnov Y, et al. Alpha-fetoprotein positively regulates cytochrome c-mediated caspase activation and apoptosome complex formation. Eur J Biochem. 2003;270:4388–99.CrossRefPubMedGoogle Scholar
  47. 47.
    Lin YS, Zhu MY, Zhou S, Xie XJ, Li MS. [effects of alpha-fetoprotein on the expression of trail death receptor-2 and its role on resisting the cytotoxicity of trail in hepatoma cells]. Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi =. Chin J Hepatol. 2010;18:745–50.Google Scholar
  48. 48.
    Li M, Li H, Li C, Wang S, Jiang W, Liu Z, et al. Alpha-fetoprotein: a new member of intracellular signal molecules in regulation of the pi3k/akt signaling in human hepatoma cell lines. Int J Cancer. 2011;128:524–32.CrossRefPubMedGoogle Scholar
  49. 49.
    Zhu MY, Guo JL, Xia H, Li W, Lu Y, Dong X, et al. [the anti-apoptotic effect of cytoplasmic alpha-fetoprotein in hepatoma cells induced by all-trans retinoic acid involves activation of the pi3k/akt signaling pathway]. Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi =. Chin J Hepatol. 2014;22:837–42.Google Scholar
  50. 50.
    Gao R, Cai C, Gan J, Yang X, Shuang Z, Liu M, et al. Mir-1236 down-regulates alpha-fetoprotein, thus causing pten accumulation, which inhibits the pi3k/akt pathway and malignant phenotype in hepatoma cells. Oncotarget. 2015;6:6014–28.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Li C, Wang S, Jiang W, Li H, Liu Z, Zhang C, et al. Impact of intracellular alpha fetoprotein on retinoic acid receptors-mediated expression of gadd153 in human hepatoma cell lines. Int J Cancer. 2012;130:754–64.CrossRefPubMedGoogle Scholar
  52. 52.
    Wang S, Jiang W, Chen X, Zhang C, Li H, Hou W, et al. Alpha-fetoprotein acts as a novel signal molecule and mediates transcription of fn14 in human hepatocellular carcinoma. J Hepatol. 2012;57:322–9.CrossRefPubMedGoogle Scholar
  53. 53.
    Li M, Li H, Li C, Guo L, Liu H, Zhou S, et al. Cytoplasmic alpha-fetoprotein functions as a co-repressor in ra-rar signaling to promote the growth of human hepatoma bel 7402 cells. Cancer Lett. 2009;285:190–9.CrossRefPubMedGoogle Scholar
  54. 54.
    Zhu M, Guo J, Xia H, Li W, Lu Y, Dong X, et al. Alpha-fetoprotein activates akt/mtor signaling to promote cxcr4 expression and migration of hepatoma cells. Oncosci. 2015;2:59–70.CrossRefGoogle Scholar
  55. 55.
    Wang B, Wang W, Niu W, Liu E, Liu X, Wang J, et al. Sdf-1/cxcr4 axis promotes directional migration of colorectal cancer cells through upregulation of integrin alphavbeta6. Carcinogenesis. 2014;35:282–91.CrossRefPubMedGoogle Scholar
  56. 56.
    Choi YH, Burdick MD, Strieter BA, Mehrad B, Strieter RM. Cxcr4, but not cxcr7, discriminates metastatic behavior in non-small cell lung cancer cells. Mol Cancer Res. 2014;12:38–47.CrossRefPubMedGoogle Scholar
  57. 57.
    Ng SA, Lee C. Hepatitis b virus x gene and hepatocarcinogenesis. J Gastroenterol. 2011;46:974–90.CrossRefPubMedGoogle Scholar
  58. 58.
    Zhang C, Chen X, Liu H, Li H, Jiang W, Hou W, et al. Alpha fetoprotein mediates hbx induced carcinogenesis in the hepatocyte cytoplasm. Int J Cancer. 2015;4.Google Scholar
  59. 59.
    von Heijne G. Patterns of amino acids near signal-sequence cleavage sites. Eur J Biochem. 1983;133:17–21.CrossRefGoogle Scholar
  60. 60.
    Mizejewski GJ. The alpha-fetoprotein third domain receptor binding fragment: in search of scavenger and associated receptor targets. J Drug Target. 2015;13:1–14.Google Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  1. 1.Division of Translational Medicine, Wadsworth CenterNew York State Department of HealthAlbanyUSA

Personalised recommendations